Selecting a Treatment Regimen
Table 5E. Characteristics of Fusion Inhibitors Drug
Formulation
Enfuvirtide (T20) Fuzeon®
▶ Injectable—supplied as lyophilized powder
▶ Each vial contains 108 mg of T20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL
Dosing Recommendations 90 mg (1 mL) subcutaneously bid
Table 5F. Characteristics of CCR5 Antagonists Drug
Formulation
Maraviroc (MVC) Selzentry®
150, 300 mg tablets
Dosing Recommendations
▶ 150 mg bid when given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r)
▶ 300 mg bid when given with NRTIs, T-20, TPV/r, NVP, and other drugs that are not strong CYP3A inhibitors or inducers
▶ 600 mg bid when given with CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)
▶ Take without regard to meals
20
